Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells

KK Dhar1,3, K Branigan1, J Parkes2, REJ Howells3, P Hand4, C Musgrove4, RC Strange1, AA Fryer1, CWE Redman3 and PR Hoban1

1Centre for Cell and Molecular Medicine, University of Keele School of Postgraduate Medicine, North Staffordshire Hospital, Stoke-on-Trent, UK; 2Department of Pathology, Stafford District General Hospital, Weston Road, Stafford, UK; 3Department of Obstetrics and Gynaecology, City General Hospital, Stoke-on-Trent, UK; 4Department of Histopathology, Central Pathology Laboratories, Stoke-on-Trent, UK

Summary The expression of cyclin D1 protein in tumour sections from 81 patients with epithelial ovarian cancer was analysed using immunohistochemistry. The tumours that overexpressed cyclin D1 in more than 10% of neoplastic cells were considered positive. Thus overexpression of cyclin D1 was observed in 72/81 (89%) of the cases examined. Protein was detected in both the nucleus and the cytoplasm in 24/81 (30%) and localized exclusively in the cytoplasm in 48/81 (59%) of the tumours. Cyclin D1 was overexpressed in both borderline and invasive tumours. There was no association between protein overexpression and tumour stage and differentiation. Furthermore, no correlation between cyclin D1 expression and clinical outcome was observed. However, in tumours overexpressing cyclin D1 (n = 72), the proportion displaying exclusively cytoplasmic localization of protein was higher in those with serous compared with non-serous histology (P = 0.004, odds ratio 4.8, 95% confidence interval 1.4–19.1). Western analysis using a monoclonal antibody to cyclin D1 identified a 36 kDa protein in homogenates from seven tumours displaying cytoplasmic only and one tumour demonstrating both nuclear and cytoplasmic immunostaining. Using restriction fragment length polymorphism polymerase chain reaction and PCR-multiplex analysis, amplification of the cyclin D1 gene (CCND1) was detected in 1/29 of the tumours demonstrating overexpression of cyclin D1 protein. We conclude that deregulation of CCND1 expression leading to both nuclear and cytoplasmic protein localization is a frequent event in ovarian cancer and occurs mainly in the absence of gene amplification. © 1999 Cancer Research Campaign

Keywords: ovarian cancer; cyclin D1; cytoplasm: nucleus; amplification; clinical outcome

A common target in carcinogenesis is de-regulation of controlled G1-S phase progression of the cell cycle (Palmero and Peters, 1996). Thus during tumourigenesis the genes encoding proteins that regulate progression through G1, frequently undergo genetic alterations. In dividing cells, the cyclin D1 gene (CCND1) acts as a growth factor sensor that responds to mitogenic signals to promote cellular proliferation. This is achieved through binding of cyclin D1 protein to specific cyclin-dependent kinases (cdk4 and cdk6). The cdk–cyclin D1 complex catalyses the phosphorylation of the retinoblastoma protein (pRB). In a hyperphosphorylated form pRb is inactivated and cells are released from G1 arrest and progress into S phase (Sherr, 1996).

In many cancers CCND1 expression is de-regulated leading to overexpression of cyclin D1 protein. This can occur through several mechanisms. For example, in some parathyroid adenomas an inversion involving 11q13 and 11q15 results in CCND1 expression coming under the control of the parathyroid hormone gene promoter (Motokura et al, 1991). In B-cell malignancies, including centrocytic B-cell lymphomas, CCND1 expression is de-regulated under the influence of the immunoglobulin heavy chain enhancer as a result of a reciprocal chromosomal translocation at the BCL1 breakpoint t(11;14)(q13;q32) (de Boer et al, 1993, 1995). Amplification of CCND1 has been described in other tumours including those of the head and neck, breast, lung, bladder, pancreas and liver (Callender et al, 1994; Gillett et al, 1994; Nishida et al, 1994; Betticher et al, 1996; Bringuier et al, 1996; Gansauge et al, 1997).

Rearrangement of the CCND1 locus resulting in protein overexpression has been associated with prognosis in a variety of malignancies. In head and neck cancers, CCND1 amplification, and protein overexpression correlates with poor prognosis (Michalides et al, 1994; Bellacosa et al, 1996). In contrast, cyclin D1 overexpression has been shown to correlate with good prognosis in non-small-cell lung cancer (NSCLC), breast cancer and bladder cancer (Betticher et al, 1996; Bringuier et al, 1996; Gillett et al, 1996). Thus a better understanding of the process of de-regulation of the control of CCND1 expression should help reveal mechanisms of carcinogenesis and also identify prognostic indicators. Most studies examining the expression of cyclin D1 in tumours have used immunohistochemistry (IHC) with monoclonal antibodies to detect the protein on paraffin-embedded tumour sections. Cyclin D1 has been detected predominantly in the nucleus, though cytoplasmic localization of protein has been described in non-Hodgkin’s lymphoma (NHL), NSCLC and some breast carcinomas (Nakamura et al, 1994, Betticher et al, 1996, Gillett et al, 1996).

Ovarian cancer has a very poor prognosis with an average 5-year survival of only 30% (Chang et al, 1994). Most patients present with unresectable, advanced disease and are candidates for chemotherapy. Some of these patients demonstrate markedly
improved survival following chemotherapy, whilst others fail to respond or develop chemoresistance. Clearly, there is a need for a greater understanding of the mechanisms involved in disease pathogenesis to allow development of preventive strategies as well as prognostic markers that could be used in patient management. Recent studies using Western analysis have shown that cyclin D1 is overexpressed in the majority of malignant ovarian tumours but is absent in benign lesions (Barbieri et al., 1997). In this analysis the subcellular localization of cyclin D1 was not determined. IHC studies have shown overexpression of cyclin D1 protein in up to 28% of malignant ovarian tumours, suggesting deregulation of cyclin D1 to be important in a sub-group of patients with the disease (Hung et al., 1996; Worsley et al., 1997). In these works only nuclear immunostaining of cyclin D1 was scored. In a pilot study we have found cytoplasmic localization of cyclin D1 in a high proportion of ovarian tumours (Dhar et al., 1997). Accordingly, we have extended this analysis to examine the frequency and subcellular localization of cyclin D1 in epithelial ovarian cancer from 81 cases. In addition we have investigated the mechanism leading to de-regulation of cyclin D1 expression and determined whether overexpression of the protein is associated with clinical outcome in women with the disease.

MATERIALS AND METHODS

Patient characteristics and materials

Eighty-one Northern European Caucasian women with histologically confirmed epithelial ovarian cancer were recruited with Ethics Committee approval and informed consent from the North Staffordshire Hospital. These patients have been described in detail (Howells et al., 1998). Tumours were staged by the criteria of the International Federation of Gynaecologists and Obstetricians (FIGO). Histological type and grade were assigned by one specialist pathologist (CM). Survival is defined as the time between diagnosis and death or the time at which the patient was last seen. Progression-free interval (PFI) is defined as the time between diagnosis and death or the time at which the patient was last seen. Paraffin-embedded ovarian tumour tissue was also obtained. Solid tumour material was collected at time of surgery, was seen. Progression-free interval (PFI) is defined as the time between diagnosis and death or the time at which the patient was

DNA extraction

DNA was extracted from paraffin sections (5 μm) using a genomic DNA extraction kit (Scotlab, Strathclyde, UK). High molecular weight DNA was extracted from frozen ovarian tissue and peripheral blood using a phenol–chloroform method as described by Sambrook et al (1989).

PCR analysis of CCND1

Imbalances within CCND1 were assessed by restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR) analysis using polymorphisms in exon 4 and the 3' UTR region of the gene as described by Betticher et al (1995, 1996). Briefly, PCR products were digested with restriction enzymes to reveal the polymorphic alleles; HaeIII (New England Biolabs, Hertfordshire, UK) for the 3'UTR polymorphism and ScrFI (New England Biolabs) for the exon 4 polymorphism. Digests were visualized on 3% agarose gels stained with ethidium bromide. Multiplex PCR was a modification of the method previously described (Betticher et al., 1996). The CCND1 gene (chromosome 11q13) was compared to the adenosine deaminase (ADA) gene (chromosome 20q12–13). The following primers were used to amplify regions of the CCND1 and ADA genes.

© 1999 Cancer Research Campaign

British Journal of Cancer (1999) 81(7), 1174–1181
Numbers in parentheses are %.

- Predominantly nuclear staining with some diffuse cytoplasmic localization.
- Simultaneous nuclear and cytoplasmic immunostaining.

Table 1  Cyclin D1 expression and localization in ovarian cancers

| Cyclin D1 level of staining | 0 (0) | + (1.2) | ++ (2.5) | +++ (4.9) | Total |
|-----------------------------|-------|---------|----------|----------|-------|
| 0  (0)                      | 9 (11.1)| 0 (0)   | 0 (0)    | 0 (0)    | 9 (11.1) |
| Positive                    |        |         |          |          |       |
| Nucleara 0 (0)              | 1 (1.2)| 2 (2.5) | 4 (4.9)  | 7 (8.6)  |       |
| Nuclear/cytoplasmicb        | 3 (3.7)| 10 (12.3)| 4 (4.9) | 17 (21)  |       |
| Cytoplasmic only 0 (0)      | 24 (29.6)| 12 (14.8)| 12 (14.8)| 48 (59.2)|       |
| Total                       | 9 (11.1)| 28 (34.6)| 24 (29.6)| 20 (24.7)| 81 (100) |

- Overexpression of cyclin D1 protein was detected in 72/81 (89%) of the epithelial ovarian cancers examined. The level of overexpression was variable between tumours and was graded accordingly (Table 1). Cyclin D1 was detected predominantly in the nuclei of tumour cells in 7/81 (9%) of the cases, and simultaneously in the nuclei and cytoplasm of tumours in 17/81 (21%). Thus 24/81 (30%) of the tumours examined displayed nuclear expression of cyclin D1. However, in 48/81 (59%) of the tumours examined expression was restricted to the cytoplasm of the tumour cells. Representative examples of simultaneous nuclear and cytoplasmic (Figure 1 A, B) and exclusively cytoplasmic staining (Figure 1 C, D) are shown. Paraffin sections obtained from normal ovarian tissue did not demonstrate cyclin D1 immunostaining (Figure 1 E).

- Western analysis of cyclin D1 expression

To investigate the specificity of the observed cytoplasmic staining for cyclin D1, we performed Western analysis and determined the size of the cross-reacting protein. Western blotting for cyclin D1 expression was performed on proteins extracted from 11 malignant tumours and two benign cysts snap-frozen at surgery. The monoclonal antibody clone 105 (Transduction Laboratories) was used to detect cyclin D1. A 36 kDa cyclin D1 protein was detected in 7/7 tumours displaying exclusively cytoplasmic immunostaining of cyclin D1 and 1/1 tumour displaying simultaneous nuclear with cytoplasmic immunostaining. Cyclin D1 was not detected in 3/3 malignant tumours negative for immunostaining (data not shown) and 2/2 benign ovarian cysts. Representative examples of cyclin D1 expression detected by Western blotting in malignant tumours displaying nuclear and cytoplasmic immunostaining, and exclusively cytoplasmic immunostaining are shown in Figure 2. The level of cyclin D1 expression varied between tumours when compared to the intensity of the vinculin blots.

- Analysis of CCND1 amplification in tumours overexpressing cyclin D1 protein

The mechanism leading to de-regulation of cyclin D1 protein expression in ovarian tumours was investigated. Tissue from 33 tumours displaying overexpression of cyclin D1 protein was available for DNA and was assessed for amplification of CCND1. Using multiplex and/or RFLP-PCR techniques on the same sample, information was available on CCND1 amplification in 29 of the tumours. Amplification of CCND1 was detected in 1/29 of these tumours. Amplification was assessed qualitatively by comparison of the intensity of ethidium bromide staining of PCR products in tumours with normal controls and the A431 cell line which displays a five-fold level of amplification of CCND1 (Kurzrock et al, 1995).
were interpreted as displaying allele imbalance at the \textit{CCND1} locus, which may be as a result of LOH of a \textit{CCND1} allele.

**Association of IHC staining of cyclin D1 with tumour characteristics**

To investigate whether cyclin D1 protein overexpression and subcellular localization was associated with prognosis, the IHC data was compared with tumour and patient characteristics. Cytoplasmic and nuclear expression of cyclin D1 protein was detected in both borderline and invasive tumours. No significant difference was found in the number of tumours staining positive for cyclin D1 or the subcellular localization of the protein when compared with tumour differentiation and FIGO stage (Table 2). However, a significant difference ($P = 0.0137$) in the distribution of immunostaining for cyclin D1 was observed when compared with tumour histology (Table 2). In addition, within tumours expressing cyclin D1 ($n = 72$), cytoplasmic localization occurred in a higher proportion of serous compared with non-serous tumours (Fisher exact test; $P = 0.004$, OR 4.84, 95% CI 1.42–19.12).

**Association of IHC staining of cyclin D1 with clinical outcome**

We compared the expression of cyclin D1 with clinical outcome in 79 patients in whom clinical follow-up data was available (Howells et al, 1998). Using Cox’s proportional hazards model we found no significant correlation between expression and subcellular localization of cyclin D1 when compared with progression-free interval (PFI) and overall survival (Figure 4). We also compared the level of expression (neg. & + vs ++ & ++++) with PFI and overall survival. The median PFI (23 months vs 23.2 months) and median survival (35 months vs 40.4 months) within these two groups were not significantly different (data not shown).

**DISCUSSION**

We have used IHC to detect cyclin D1 overexpression in 81 epithelial ovarian cancers. We found a large proportion of the tumour studied demonstrated overexpression of cyclin D1 as determined by IHC, has previously been described in ovarian tumours (Hung et al, 1996; Worsley et al, 1997). Hung et al reported overexpression in 28% of cases examined using a polyclonal cyclin D1 antibody whilst Worsley et al detected overexpression of cyclin D1 in up to 26% of tumours using a mouse monoclonal antibody (mAb). The lower number of cases overexpressing cyclin D1 reported in these earlier studies may reflect that only nuclear expression of cyclin D1 was scored. In our series, nuclear expression of cyclin D1 occurred in 30% of ovarian tumours which compares favourably with previous reports.
Figure 2. Expression of cyclin D1 (36 kDa) protein in epithelial ovarian tumours. Lysates from malignant tumours displaying cytoplasmic (lanes 1, 3 & 4) and nuclear/cytoplasmic (lane 2) expression of cyclin D1 (as determined by IHC) are shown. Lane 5 contains lysate extracted from a benign ovarian cyst. Membranes were probed with: (A) monoclonal antibody for cyclin D1, the position of the 36 kDa protein is shown left; (B) levels of protein loading were visualized by stripping the membrane and re-probing with a monoclonal antibody for vinculin.

Figure 3. Analysis of CCND1 amplification in ovarian tumours. (A) RFLP-PCR analysis of CCND1; PCR products were digested with ScrFI (lanes 2–7) or HaeIII (lanes 8–11) and separated on 3% agarose gels stained with ethidium bromide. Lane 1; ØX 174 HaeIII digest, lane 2; normal lymphocytes, lane 3; lymphocytes patient 51, lane 4; tumour patient 51, lane 5; normal lymphocytes patient 323, lane 6; tumour patient 323, lane 7; A431. Lane 8; normal lymphocytes, lane 9; normal lymphocytes patient 51, lane 10; tumour patient 51, lane 11; A431. (B) Multiplex PCR analysis of ovarian tumours to determine amplification of CCND1. PCR products for CCND1 and ADA, shown left were separated on 3% agarose gels. Lane 1; A431 DNA, lane 2; tumour 51, lane 3; tumour 323, lane 4; normal lymphocytes, lane 5; ØX 174 HaeIII digest.

Table 2 Association of cyclin D1 expression with ovarian tumour characteristics

| Cyclin D1 Immunostaining | Nuclear | Cytoplasmic | Negative |
|--------------------------|---------|-------------|----------|
| Age at diagnosis (years) |         |             |          |
| Range                    | 36–74   | 28–90       | 46–80    |
| Median                   | 59.5    | 61.5        | 74       |
| Tumour differentiation   |         |             |          |
| Borderline               | 2 (25.0)| 5 (62.5)    | 1 (12.5) |
| Well                     | 4 (57.1)| 3 (42.9)    | 0 (–)    |
| Moderate                 | 10 (33.3)| 17 (56.7)  | 3 (10)   |
| Poor                     | 5 (28.8)| 15 (62.5)   | 4 (16.7) |
| Not mentioned            | 3 (25.0)| 8 (66.7)    | 1 (8.3)  |
| FIGO stage               |         |             |          |
| I                        | 11 (42.3)| 14 (53.9)   | 1 (3.8)  |
| II                       | 2 (22.2)| 6 (66.7)    | 1 (11.1) |
| III                      | 9 (22.5)| 24 (60.0)   | 7 (17.5) |
| IV                       | 2 (33.3)| 4 (66.7)    | 0 (–)    |
| Histology                |         |             |          |
| Endometroid              | 7 (50)  | 6 (42.9)    | 1 (7.1)  |
| Serous*                  | 5 (13.5)| 27 (73.0)   | 5 (13.5) |
| Clear cell               | 4 (36.3)| 6 (54.6)    | 1 (9.1)  |
| Mucinous                 | 6 (46.2)| 7 (53.8)    | 0 (–)    |
| Other/Mixed              | 2 (33.3)| 2 (33.3)    | 2 (33.3) |

Figures in parenthesis are %. *The distribution of immunostaining in serous tumours was significantly different compared with other histological types. (Fisher exact test, \( P = 0.0137, \chi^2 = 8.44 \)).
Recently using Western analysis, cyclin D1 protein was detected in 90% of the malignant ovarian tumours examined (Barbieri et al., 1997). The high level of cyclin D1 overexpression in this study compared with previous findings (Hung et al., 1996; Worsley et al., 1997) may reflect differences in sensitivity of detection of Western blotting compared with IHC. However, Barbieri et al. did not determine subcellular localization of the protein, which prompted us to consider the significance of cytoplasmic staining for cyclin D1. To investigate the specificity of cytoplasmic immunostaining of cyclin D1, we used Western analysis of extracted proteins from tumours demonstrating overexpression of cyclin D1. We used a different cyclin D1 mAb for the Western analysis (clone 105) than that used for IHC (clone DCS-6). Both antibodies identify a 36 kDa protein in Western analysis of a panel of cell lines (data not shown), although in our hands DCS-6 is not as specific as clone 105 in Western blots on ovarian tumour material. Furthermore, clone 105 was not suitable for IHC. Analysis of tumours displaying exclusively cytoplasmic overexpression of cyclin D1 and a tumour displaying simultaneous nuclear and cytoplasmic expression revealed a 36 kDa band with clone 105. We were unable to detect expression of cyclin D1 by Western analysis in three tumours negative by IHC, as well as benign ovarian cysts. Together the IHC and Western data consolidate our findings of frequent cytoplasmic overexpression of cyclin D1 in our cohort of tumours. It is possible, however, that the two antibodies may recognize different cyclin D1 epitopes and further may hybridize to other cyclin D1 protein variants. It has been shown that CCND1 mRNA is alternatively spliced (Betticher et al., 1995) and that DCS-6 recognizes both proteins encoded from the alternate transcripts in vitro expression studies (Sawa et al., 1998). Future studies including immunoprecipitation experiments are needed to further characterize cytoplasmic cyclin D1 protein in ovarian tumours.

In many cancers overexpression of cyclin D1 protein is associated with tumour characteristics and clinical outcome. The localization of the cyclin D1 protein may have implications for the diagnosis and prognosis in cancer. In NHL localization of cyclin D1 has been implicated in patient prognosis (Nakamura et al., 1994). Thus in mantle cell lymphomas (MCL), generally associated with poor prognosis, frequent chromosomal translocation t(11;14)(q13;q32) leads to strong nuclear overexpression of cyclin D1 protein and distinguishes the malignancy from other types of NHL (Nakamura et al., 1994; de Boer et al., 1995). Nakamura et al. also describe a pattern of cytoplasmic immunoreactivity in diffuse B-cell and follicular B-cell NHL which are prognostically different to MCL. In ovarian cancers, we found no correlation between overexpression and localization of cyclin D1 protein with tumour stage or differentiation. However, cytoplasmic localization of cyclin D1 protein occurred more frequently in serous compared with non-serous tumours. A correlation between nuclear expression of cyclin D1 and well-differentiated and borderline malignancy in a series of 43 ovarian tumours has been described (Worsley et al., 1997). The differences of our findings may reflect the larger number of tumours studied. We did not find any significant associations between cyclin D1 overexpression and subcellular localization with PFI and overall survival of patients. It has been shown that overexpression of cyclin D1 mRNA in epithelial ovarian cancers does not correlate with clinical outcome (Masciullo et al., 1997); however, to date no study has examined expression of cyclin D1 protein with clinical outcome.

The mechanism of cyclin D1 protein overexpression in ovarian cancer is unclear. Amplification of CCND1 in ovarian tumours is infrequent (Courjal et al., 1996; Masciullo et al., 1997); however, in these studies cyclin D1 protein levels were not measured. We examined CCND1 amplification in tumours overexpressing cyclin D1 protein as determined by IHC; 28/29 of these tumours did not demonstrate amplification of CCND1. However, 5/24 of the tumours displayed allele imbalance of CCND1 using RFLP-PCR, but an absence of imbalance of CCND1 using PCR multiplex analysis. These findings may result from LOH at the CCND1 locus in these tumour cells. High levels of LOH at 11q have been previously described in epithelial ovarian cancers though there is no evidence to suggest that CCND1 is the target of the LOH in this region (Foulkes et al., 1993; Gabra et al., 1996). Overexpression of cyclin D1 in the absence of gene amplification has been reported in NSCLC and breast cancer (Gillett et al., 1994; Betticher et al., 1996). Clearly mechanisms other than CCND1 amplification may lead to overexpression of cyclin D1 protein. To date no in vivo abnormalities to CCND1 have been described that influence intracellular localization of the protein. In vitro mutations to CCND1 have been shown to influence the localization of cyclin D1–cdk4 protein complexes to the cytoplasm in mouse cells (Diehl and Sherr, 1997). In this study, nuclear localization could be achieved through overexpression of the cdk inhibitor p21. It has been suggested that cdk inhibitors including p21 may have additional roles as adaptor proteins involved in the assembly and intracellular localization of cyclin D1 complexes.

![Figure 4](image-url) Kaplan–Meier survival plots showing the association between cyclin D1 expression and (A) progression-free interval and (B) survival, in patients with epithelial ovarian cancer.
localization of kinase complexes (LaBaer et al., 1997). No mutations in CCND1 coding sequences were found in NSCLC cells displaying cyttoplasmic only expression (Betticher et al., 1995). It is possible however that localization of cyclin D1 to the cytoplasm in ovarian tumours results from mutations to other genes encoding proteins with which it complexes.

Understanding the function of cyttoplasmic cyclin D1 in ovarian tumours may be important clinically. In the nucleus cyclin D1 facilitates cell cycle progression. Thus overexpression of cyclin D1 protein in vitro is associated with increased proliferation (Quelle et al., 1993; Musgrove et al., 1994). However, paradoxically, cyclin D1 overexpression has also been associated with apoptosis (Kranenburg et al., 1996; Kotelnikov et al., 1997) and cellular senescence (Dulic et al., 1993; Lucibello et al., 1993). The function of cyttoplasmic cyclin D1 described in this study has not been addressed. However, it would be interesting to investigate the expression of cdk4 or the status of pRB in these tumours. In addition a cyttoplasmic substrate for cdk4 and cdk6 has been described (Kwon et al., 1995). Furthermore, although predominantly nuclear during the G1 phase of the cell cycle, cyclin D1 and D2 in dividing U-2-OS cells demonstrate cyttoplasmic localization at G1/S transition (Lukas et al., 1994).

In conclusion, overexpression of cyclin D1 leading to cyttoplasmic and nuclear protein localization is a frequent event in ovarian cancer occurring mainly in the absence of CCND1 amplification. A better knowledge of the mechanisms involved in deregulation of cyclin D1 expression and the biological consequence of this, may ultimately lead to the development of improved strategies for the treatment of ovarian cancer.

ACKNOWLEDGEMENTS

We would like to thank the West Midlands NHS Executive, Locally Organised Research Scheme for supporting this work.

REFERENCES

Barbieri F, Cagnoli M, Ragni N, Pedulla F, Foglia G and Alama A (1997) Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br J Cancer 75: 1263–1268
Bellacosa A, Almadori G, Cavallo S, Cadoni G, Galli J, Ferrandina G, Scambia G and Neri G (1996) Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 2: 175–180
Betticher DC, Heighway J, Haselton PS, Altermatt HJ, Ryder WDJ, Cerny T and Thatcher N (1996) Cyclin D1 and EMS1 in bladder tumours: relationship with chromosome 11q13 amplification. Proc Natl Acad Sci USA 93: 11034–11038
Foulkes WD, Campbell IG, Stoppa L and Twose J (1993) Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer 67: 268–273
Gabra H, Watson JEV, Taylor KJ, Mackay J, Leonard RC, Steel CM, Porteous DJ and Smyth JF (1996) Definition and refinement of loss of heterozygosity at 11q23.4–24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 56: 950–954
Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N and Beger H (1997) Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57: 1634–1637
Gillett C, Fanti V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D and Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54: 1812–1817
Gillett C, Smith P, Gregory W, Richards M, Mills R, Peters G and Barnes D (1996) Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69: 92–99
Howells REJ, Redman CWE, Dhar KK, Sarhanis P, Musgrove C, Jones PW, Alderseja I, Fryer AA, Hoban P and Strange RC (1998) Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res 4: 2439–2445
Hung W-C, Chai C-Y, Huang J-S and Chuang L-Y (1996) Expression of cyclin D1 and c-Ki-ras gene in human epithelial ovarian tumours. Hum Pathol 27: 1324–1328
Kotelnikov VM, Coon JS, Mundle S, Kelanic S, LaFollette S, Taylor IVS, Hutchinson J, Panje W, Caldarella DD and Preissler HD (1997) Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res 3: 95–101
Kranenborg O, van der El J and Zantema A (1996) Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 15: 46–54
Kurzrock R, Ku S and Talpaz M (1995) Abnormalities in the PRAD1 (CCND1) oncogene are frequent in cervical and vulval squamous cell carcinoma cell lines. Cancer 75: 584–590
Kwon TK, Buchholz MA, Gabrielson EW and Nordin AA (1995) A novel cyttoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells. Oncogene 11: 2077–2083
La Baer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattayia A and Harlow E (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847–862
Lukas J, Bartkova J, Welcker M, Petersson O, Peters G, Strauss M and Bartek J (1995) Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types.
Manciulli V, Scambia G, Marone M, Giannetti C, Ferrandina G, Bellacosa A, Beneditti Panci P and Mancus OS (1997) Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int J Cancer 74: 390–395
Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E and Balm A (1995) Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55: 975–978
Motokura T, Bloem T, Kim HG, Jupin P, Rudeerman JV, Kronenberg HM and Arnold A (1991) A novel cyclin encoded by a bcl-1 linked candidate oncogene. Nature 350: 512–515
Musgrove EA, Lee CS, Buckley MF and Sutherland RL (1994) Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 91: 8022–8026
Nakamura S, Seto M, Banno S, Suzuki S, Koshikawa T, Kitoh K, Kagami Y, Ogura M, Yatabe Y, Kojima M, Motoo T, Takahashi T, Ueda R andSuchi T (1994)

Immunohistochemical analysis of cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma. *Jpn J Cancer Res* **85**: 1270–1279

Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomori M, Shibagaki I, Nakao K, Ikenaga M and Ishizaki K (1994) Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. *Cancer Res* **54**: 3107–3110

Palmero I and Peters G (1996) Perturbation of cell cycle regulators in human cancer. *Cancer Surveys* **27**: 351–367

Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF and Sherr CJ (1993) Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. *Genes Dev* **7**: 1559–1571

Sambrook J, Fritsch EF and Maniatis T (1989) *Molecular Cloning: A Laboratory Manual*, 2nd edn. Cold Spring Harbor Laboratory Press: Cold Spring Harbor NY, USA

Sawa H, Ohshima TA, Ukiti H, Murakami H, Chiba Y, Kamanda H, Hara M and Saito I (1998) Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. *Oncogene* **16**: 1701–1712

Sherr CJ (1996) Cancer cell cycles. *Science* **274**: 1672–1677

Worsley S, Ponder BAJ and Davies BR (1997) Overexpression of cyclin D1 in epithelial ovarian cancers. *Gynecol Oncol* **64**: 189–195